<DOC>
	<DOCNO>NCT00182455</DOCNO>
	<brief_summary>SSRI 's consider first-line treatment GSP , however many patient continue significant symptom despite adequate trial SSRI . Topiramate , drug , target glutamate system brain , show improve symptom social phobia use also used additive treatment anxiety disorder . This study test efficacy add topiramate subject 's current SSRI case GSP consider treatment-resistant .</brief_summary>
	<brief_title>Efficacy Adding Topiramate Current Treatment Treatment-Resistant Generalized Social Phobia ( GSP )</brief_title>
	<detailed_description />
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Outpatient primary DSMIV GSP Completion adequate trial ( 14 wks ) open , flexible dose SSRI treatment ( fluoxetine 80mg/day , paroxetine 60mg/day , fluvoxamine 300 mg/day , sertraline 200mg/day , citalopram 60mg/day , escitalopram 30mg/day ) Non partial response SSRI treatment ( CGIS &gt; 4 , LSAS &gt; 40 ) Any DSMIV Axis I primary diagnosis Meeting DSMIV criterion body dysmorphic disorder , eat disorder current alcohol/substance abuse A lifetime history bipolar affective disorder A Hx schizophrenia/psychotic disorder , delirium , dementia , amnestic/other cognitive disorder Borderline/antisocial personality disorder A comorbid Axis II cluster A personality disorder Hx &gt; 3 adequate trial SSRI score &gt; 4 MADRS q.10 Current increase risk suicide Prior use allergy topiramate Participation clinical trial 30 day prior enter study Unable tolerate free show sign withdrawal benzodiazepines 4 week Hx seizure , kidney stone thyroid problem BMI &lt; 20</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Treatment Refractory Generalized Social Phobia</keyword>
</DOC>